| Website | xigenpharma.com |
| Category | BioTech |
| Phone | +41.21.321.10.80 |
| Employees | |
| Founded | 2002 |
| Description | Intracellular protein interactions |
| TOTAL | $41M |
| FUNDING TOTAL | $41M |
| Series A, 9/05 Tilocor Life Science Initiative Capital VI Partners | $21M |
| Series B, 11/09 Tilocor Life Science | $20M |
Xigen SA is a private Swiss biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) in Switzerland. Dr. Christophe Bonny, CEO and co-founder, is a renowned molecular biologist with over a decade’s research expertise on intracellular peptides and signalling.
